Domenico Albano1, Giovanni Bosio2, Chiara Pagani3, Alessandro Re3, Alessandra Tucci3, Raffaele Giubbini2, Francesco Bertagna2. 1. Nuclear Medicine, University of Brescia and Spedali Civili Brescia, P.le Spedali Civili 1, 25123, Brescia, Italy. doalba87@libero.it. 2. Nuclear Medicine, University of Brescia and Spedali Civili Brescia, P.le Spedali Civili 1, 25123, Brescia, Italy. 3. Division of Hematology, Spedali Civili, Brescia, Italy.
Abstract
PURPOSE: Burkitt's lymphoma (BL) is an aggressive lymphoma subtype with high 18F-FDG avidity at 18F-FDG-PET/CT, but no validated criteria for PET/CT in treatment evaluation or prediction of outcome in BL are available. The aim of our study was to investigate whether the metabolic baseline PET/CT parameters can predict treatment response and prognosis in BL. MATERIALS AND METHODS: We retrospectively enrolled 65 patients who underwent baseline 18F-FDG-PET/CT, interim and end of treatment PET/CT. The PET images were analyzed visually and semi-quantitatively by measuring the maximum standardized uptake value body weight (SUVbw), the maximum standardized uptake value lean body mass (SUVlbm), the maximum standardized uptake value body surface area (SUVbsa), lesion to liver SUVmax ratio (L-L SUV R), lesion to blood-pool SUVmax ratio (L-BP SUV R), total metabolic tumor volume (tMTV) and total lesion glycolysis (TLG). Survival curves were plotted according to the Kaplan-Meier method. RESULTS: At a median follow-up of 40 months, the median PFS and OS were 34 and 39 months. MTV and TLG were significantly higher in patients with partial response compared to complete response group at end of treatment, while no significant differences were found at interim. Other metabolic PET/CT parameters were not related to treatment response. MTV and TLG were demonstrated to be independent prognostic factors for both PFS and OS; instead SUVbw, SUVlbm, SUVbsa, L-L SUV R and L-BP SUV R were not related to outcome survival. CONCLUSIONS: Metabolic tumour features (MTV and TLG) were significantly correlated with response to treatment and long-term outcome.
PURPOSE:Burkitt's lymphoma (BL) is an aggressive lymphoma subtype with high 18F-FDG avidity at 18F-FDG-PET/CT, but no validated criteria for PET/CT in treatment evaluation or prediction of outcome in BL are available. The aim of our study was to investigate whether the metabolic baseline PET/CT parameters can predict treatment response and prognosis in BL. MATERIALS AND METHODS: We retrospectively enrolled 65 patients who underwent baseline 18F-FDG-PET/CT, interim and end of treatment PET/CT. The PET images were analyzed visually and semi-quantitatively by measuring the maximum standardized uptake value body weight (SUVbw), the maximum standardized uptake value lean body mass (SUVlbm), the maximum standardized uptake value body surface area (SUVbsa), lesion to liver SUVmax ratio (L-L SUV R), lesion to blood-pool SUVmax ratio (L-BP SUV R), total metabolic tumor volume (tMTV) and total lesion glycolysis (TLG). Survival curves were plotted according to the Kaplan-Meier method. RESULTS: At a median follow-up of 40 months, the median PFS and OS were 34 and 39 months. MTV and TLG were significantly higher in patients with partial response compared to complete response group at end of treatment, while no significant differences were found at interim. Other metabolic PET/CT parameters were not related to treatment response. MTV and TLG were demonstrated to be independent prognostic factors for both PFS and OS; instead SUVbw, SUVlbm, SUVbsa, L-L SUV R and L-BP SUV R were not related to outcome survival. CONCLUSIONS:Metabolic tumour features (MTV and TLG) were significantly correlated with response to treatment and long-term outcome.
Authors: Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544
Authors: A S Cottereau; S Becker; F Broussais; O Casasnovas; S Kanoun; M Roques; N Charrier; S Bertrand; R Delarue; C Bonnet; R Hustinx; P Gaulard; L de Leval; P Vera; E Itti; N Mounier; C Haioun; H Tilly; M Meignan Journal: Ann Oncol Date: 2016-01-19 Impact factor: 32.976
Authors: Dimitrios Karantanis; Jolanta M Durski; Val J Lowe; Mark A Nathan; Brian P Mullan; Evangelos Georgiou; Patrick B Johnston; Gregory A Wiseman Journal: Eur J Radiol Date: 2009-08-27 Impact factor: 3.528
Authors: N George Mikhaeel; Daniel Smith; Joel T Dunn; Michael Phillips; Henrik Møller; Paul A Fields; David Wrench; Sally F Barrington Journal: Eur J Nucl Med Mol Imaging Date: 2016-02-23 Impact factor: 9.236
Authors: Yeye Zhou; Zixuan Zhao; Yiwei Wu; Jihui Li; Bin Zhang; Shibiao Sang; Shengming Deng Journal: Cancer Manag Res Date: 2019-07-23 Impact factor: 3.602
Authors: Imke E Karsten; Gabriele Reinartz; Michaela Pixberg; Kai Kröger; Michael Oertel; Birte Friedrichs; Georg Lenz; Hans Theodor Eich Journal: Biomedicines Date: 2021-05-17
Authors: Sarah A Milgrom; Jihyun Kim; Alin Chirindel; Jongho Kim; Qinglin Pei; Lu Chen; Allen Buxton; Sandy Kessel; Jeffrey Leal; Kathleen M McCarten; Bradford S Hoppe; Suzanne L Wolden; Cindy L Schwartz; Debra L Friedman; Kara M Kelly; Steve Y Cho Journal: Pediatr Blood Cancer Date: 2021-07-10 Impact factor: 3.838